NDA 215866 · Eli Lilly and CO
Mounjaro
Tirzepatide · Subcutaneous · Glucose-dependent Insulinotropic Polypeptide Receptor Agonist; GLP-1 Receptor Agonist
NovelPriority reviewCDER novel approval, May 13, 2022: To improve blood sugar control in diabetes, in addition to diet and exercise
Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2022
May 13, 2022
Approved uses
4
Original approval plus efficacy supplements
Registered trials
242
59 Phase 3, 94 recruiting
FAERS reports
100,728
27,362 serious, 887 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In both male and female rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ) and Nonclinical Toxicology ( 13.1 )]. MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Contraindications ( 4 )] . Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin...
What it is approved for
From the label in effect Aug 27, 2026.
MOUNJARO ® is indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction (MI), or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. MOUNJARO ® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated: as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. ( 1 ) to reduce the risk of major adverse cardiovascular (CV) events (CV death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who are at high risk for these events. ( 1 )
Mechanism: Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It contains a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1. Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 27, 2026 Supplement 44 · Efficacy LetterLabel
- Aug 27, 2026 Supplement 45 · Efficacy LetterLabelMedication Guide
- Dec 19, 2025 Supplement 39 · Efficacy · priority review LabelLetter
- May 13, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
24 products under this application
- MOUNJARO · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO KWIKPEN · TIRZEPATIDE 60MG/2.4ML (25MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO KWIKPEN · TIRZEPATIDE 40MG/2.4ML (16.7MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO KWIKPEN · TIRZEPATIDE 20MG/2.4ML (8.33MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 15MG/0.5ML (15MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 10MG/0.5ML (10MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 5MG/0.5ML (5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO KWIKPEN · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO KWIKPEN · TIRZEPATIDE 50MG/2.4ML (20.8MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO KWIKPEN · TIRZEPATIDE 30MG/2.4ML (12.5MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 10MG/2.4ML (4.17MG/ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO · TIRZEPATIDE 12.5MG/0.5ML (12.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 7.5MG/0.5ML (7.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
- MOUNJARO (AUTOINJECTOR) · TIRZEPATIDE 2.5MG/0.5ML (2.5MG/0.5ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Tirzepatide" as an intervention, any sponsor and status, largest first.
- A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With ObesityPivotal-lookingActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT05556512 · 15,374 participants · Start Oct 11, 2022 · Primary completion Oct 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight
Sites: Gilbert, Arizona; Mesa, Arizona; Phoenix, Arizona · 672 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07165028 · 4,500 participants (planned) · Start Oct 15, 2025 · Primary completion Aug 2030
Drug: Tirzepatide; Retatrutide and 1 more · For: Metabolic Dysfunction-Associated Steatotic Liver Disease
Sites: Tuscaloosa, Alabama; Chandler, Arizona; Gilbert, Arizona · 563 sites in all
- A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)Pivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07247084 · 3,000 participants (planned) · Start Nov 24, 2025 · Primary completion Jul 2029
Drug: Tirzepatide · For: Obesity
Sites: Altrincham, United Kingdom; Ashton-under-Lyne, United Kingdom; Bolton, United Kingdom · 30 sites in all
- Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)Pivotal-lookingRecruiting
Hudson BiotechIndustry
NCT07481747 · 2,539 participants (planned) · Start Feb 2, 2026 · Primary completion Feb 14, 2027
Drug: Tirzepatide; Placebo · For: Obesity; Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities
Sites: Shenzhen, China
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04184622 · 2,539 participants · Start Dec 4, 2019 · Primary completion Apr 1, 2022
Drug: Tirzepatide; Placebo · For: Overweight; Obesity
Sites: Pelham, Alabama; Scottsdale, Arizona; Concord, California · 118 sites in all
- A Study of EloraTZP in Adult Participants With Obesity Without Type 2 DiabetesPivotal-lookingNot yet recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT07881432 · 2,115 participants (planned) · Start Dec 2026 · Primary completion Oct 2029
Drug: eloralintide and tirzepatide; Eloralintide and 2 more · For: Obesity
Sites: Mesa, Arizona; Scottsdale, Arizona; Tucson, Arizona · 161 sites in all
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular RiskPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03730662 · 2,002 participants · Start Nov 20, 2018 · Primary completion Jan 22, 2021
Drug: Tirzepatide; Insulin Glargine · For: Type 2 Diabetes Mellitus
Sites: Anaheim, California; Covina, California; Greenbrae, California · 216 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- incorrect dose administered17,484
- nausea10,241
- injection site pain9,528
- off label use8,262
- diarrhoea6,368
- vomiting5,525
- extra dose administered5,273
- constipation3,915
- injection site haemorrhage3,644
- product dose omission issue3,451
- injection site erythema3,219
- blood glucose increased3,088
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 6 |
| 2017 | 6 |
| 2018 | 3 |
| 2019 | 24 |
| 2020 | 30 |
| 2021 | 32 |
| 2022 | 5,039 |
| 2023 | 20,764 |
| 2024 | 22,632 |
| 2025 | 31,711 |
| 2026 | 20,481 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Mounjaro (Tirzepatide)
2024 spending
$6.34B
Beneficiaries
894,581
5,105,397 claims
Per beneficiary
$7,084
$511.63 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $144,035,152 |
| 2023 | $2,361,384,157 |
| 2024 | $6,336,942,641 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.
Yao H, Zhang A, Li D, et al. · BMJ 2024 · Systematic Review, Network Meta-Analysis
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP, Davies MJ, Rosenstock J, et al. · N Engl J Med 2021 · Clinical Trial, Phase III, Comparative Study
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
Jastreboff AM, le Roux CW, Stefanski A, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial.
Zhao L, Cheng Z, Lu Y, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
Aronne LJ, Sattar N, Horn DB, et al. · JAMA 2024 · Clinical Trial, Phase III, Multicenter Study
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
Aronne LJ, Horn DB, le Roux CW, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
Sponsor: Eli Lilly · Also marketed as Mounjaro Kwikpen, Mounjaro (Autoinjector)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.